| Species |
Human |
| Protein Construction |
PGLYRP1 (Gln22-Pro196)_x000D_
Accession # O75594 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
PGLYRP1 hFc Chimera, Human captured on CM5 Chip via Protein A can bind Human TREM1, His Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
46.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Innate immunity protein Tag7 (PGRP-S, PGLYRP1) can interact with the TNFα receptor, TNFR1, and block the transduction of apoptotic signals through this receptor. A complex formed between the Tag7 protein and the major heat shock protein Hsp70 can activate TNFR1 receptor and induce tumor cell death via either apoptotic or necroptotic pathway. |
| Synonyms |
PGRP-S; PGLYRP1; PGLYRP; PGRP; TNFSF3L; PGRP-SMGC126894; PGRPSMGC126896; TAG7; Tasg7 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
